Exacerbation of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid by the immune checkpoint inhibitors durvalumab and tremelimumab
Shinichiro Inoue
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorCorresponding Author
Yosuke Mai
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Correspondence
Yosuke Mai, Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan.
Email: [email protected]
Search for more papers by this authorJoohyung Youh
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorMayuna Shimano
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorShiori Hikichi
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorHideyuki Kosumi
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorInkin Ujiie
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorKentaro Izumi
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorMakoto Usami
Department of Medical Oncology, Steel Memorial Muroran Hospital, Muroran, Japan
Search for more papers by this authorHideyuki Ujiie
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorShinichiro Inoue
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorCorresponding Author
Yosuke Mai
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Correspondence
Yosuke Mai, Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan.
Email: [email protected]
Search for more papers by this authorJoohyung Youh
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorMayuna Shimano
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorShiori Hikichi
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorHideyuki Kosumi
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorInkin Ujiie
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorKentaro Izumi
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this authorMakoto Usami
Department of Medical Oncology, Steel Memorial Muroran Hospital, Muroran, Japan
Search for more papers by this authorHideyuki Ujiie
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Search for more papers by this author
REFERENCES
- 1Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013; 381: 320–332.
- 2Izumi K, Nishie W, Mai Y, Wada M, Natsuga K, Ujiie H, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol. 2016; 136: 2201–2210.
- 3Ujiie H. What's new in the pathogeneses and triggering factors of bullous pemphigoid. J Dermatol. 2023; 50: 140–149.
- 4Sugiyama S, Yamamoto T, Aoyama Y. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: a nationwide retrospective observational study. J Dermatol. 2022; 49: 697–702.
- 5Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis VA. Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Front Immunol. 2023; 14:1197364.
